over the last decade due to the progress in resection criteria and locoregional treatment techniques, the prognosis of HCC remains poor, with a high incidence of local recurrence and distant metastases. 2 Currently, no adjuvant therapy for HCC is recommended after curative treatment in prevailing guidelines. There is also a pressing need for more effective treatment options that would result in more prolonged survival and in reducing tumour recurrence.
Recently, cancer immunotherapy has emerged as an appealing field in eliminating the micrometastatic and residual disease of cancer, 3 among which cytokine-induced killer (CIK) cells therapy is a promising option.
CIK cells are activated lymphocytes, generated by expanding mononuclear cells in peripheral blood with cytokines comprising IFN-γ, IL-2 and anti-CD3 antibody. 4 Clinical studies have shown that adoptive CIK cells therapy has potent antitumour effects and can improve the prognosis of a variety of malignancies. 5 For HCC, adjuvant CIK therapy has been demonstrated effective in prolonging patients' survival in accumulating study. 5 However, the survival benefit of CIK cells therapy varied significantly between HCC patients. Biomarkers that can differentiate between responders and non-responders are warranted for personalized treatment.
There is emerging evidence that immune escape and cancer immunoresistance play an essential role in tumour recurrence. and PD-L2. The PD-1-PD-L1 engagement blocks T-cell receptor signalling, inhibits T-cell proliferation and contributes to T-cell exhaustion, which is a crucial mechanism of immune evasion by tumours. 6 The immunohistochemical expression of PD-1/PD-L1 has been correlated with the treatment response of PD-1 blockade immunotherapy in various malignancies. 7 In addition, the PD-1 expression on tumour-infiltrative lymphocytes (TILs) can predict antitumor responses of TILs, a kind of adoptive cellular immunotherapy. 8, 9 A recent study found that high intratumoral PD-L1 expression in HCC correlated with an improved treatment response of CIK cells therapy 10 ; however, in their research, PD-L1 expression was the only immune-related factor investigated, the predictive value This study aimed to characterize the expression of PD-1 on TILs and PD-L1 on tumour cells and to determine whether the number of PD-1 + TILs was a more potent biomarker than PD-L1 expression in predicting the response of CIK cells treatment. 
| MATERIALS AND METHODS

| Patient selection
| Surgical resection and CIK cells treatment
Curative resection was performed by experienced surgeons. For patients who suffered tumour recurrence, apart from a second resection, other therapies (TACE, RFA, SIRT and sorafenib) were decided by a multidisciplinary group, which consisted of physicians, interventional radiologists and oncologists.
Key points
• CIK cell therapy improves the prognosis of HCC patients after curative resection.
• No association between PD-1 + TILs and patient survival in the surgery-only group.
• PD-1 + TILs could predict the efficacy of CIK treatment received by HCC patients.
• The correlation between high number of PD-1 + TILs and the high number of both CD4 + and CD8 + TILs suggested that PD-1 + TILs can reflect the existence of endogenous host immune response to tumours.
The preparation of CIK cells was described in our previous studies 11 and the CIK cells treatment assignment schedule is shown in Figure S2 .
More detailed information can be found in supplementary materials.
| Immunohistochemical (IHC) staining
All of the 290 patient tumour tissue samples were analysed immunohistochemically. The detailed method of IHC was provided in supplementary materials.
| Quantification of PD-1/PD-L1 expression and immune cell infiltration
The degree of immunostaining was scored independently by two observers in a blind manner. The interobserver agreements (Fleiss' kappa value) for each IHC staining factor between the two observers were shown in Table S1 .
The proportion of PD-L1 positive cells of total tumour cells was scored as the percentages: ≥5%, 1%-5% and <1%; the tumour positivity was defined using the cut-off of 5%, based on previous studies. The number of Foxp3 + TILs, CD4 + TILs and CD8 + TILs was evaluated according to the previous studies. 14, 15 The detailed method was provided in Supporting information.
| Follow-up and statistical methods
The median follow-up time for the surgery-CIK group and the surgeryonly group was 98.7 months (9-120 months) and 83.0 months (4-105 months) respectively. The primary endpoint was disease-free survival (DFS) and the second endpoint was overall survival (OS). 
| RESULTS
| Baseline characteristics and prognosis of surgery-CIK and surgery-only groups
The baseline data for the population are described in Table S2 . After one-to-one propensity score matching, 145 pairs of patients from the surgery-CIK group and surgery-only group were matched (Table   S3 ). All the patients in the surgery-CIK group finished the four cycles of CIK infusion; almost 50% of patients received additional cycles of CIK infusions. 26 (17.9%) patients received more than 16 cycles CIK infusions (Table S4 ). There were no significant differences in the F I G U R E 1 Kaplan-Meier curves for the analysis of differences in survival between surgery-CIK group and surgery-only group in HCC patients. (A) Overall survival (OS) and (B) disease-free survival (DFS). P values were calculated by log-rank test distribution of all clinicopathological characteristics between the two groups except the HBV history (P = .031).
Univariate analysis suggested that the surgery-CIK group had a significantly higher DFS (P = .001) and OS (P = .040) rates as to the surgery-only group (Figure 1 (Table S5-S6) .
Further analysis showed patients receiving CIK immunotherapy could significantly reduce the risk of intrahepatic distant recurrence (beyond 2 cm from margin and less than 2 years after resection, P = .047) and intrahepatic de novo origins (more than 2 years after resection, P = .016) ( Figure S3) 
| Adverse effects of CIK cells therapy
Adverse effects of CIK treatment was shown in supplementary materials.
| PD-1 and PD-L1 expression pattern in HCC tissue samples
To investigate the expression of PD-1 and PD-L1 in tumours, we con- 
| PD-1/PD-L1 expression, clinical and immunological features and survival benefit from adjuvant CIK cells immunotherapy
The prognostic values of PD-1/PD-L1 expression in both the surgery-CIK group and surgery-only group were compared. Regarding OS, univariate analysis showed that, in the surgery-CIK group, both PD-L1 expression and number of PD-1 + TILs were significantly associated with improved OS (Figure 3A and C). In the surgery-only group, these associations were insignificant ( Figure 3E and G). Regarding DFS, in the surgery-CIK group, univariate analysis showed that high number of PD-1 + TILs was associated with improved DFS ( Figure 3D ).
While in the surgery-only group, the association was insignificant ( Figure 3H ). In addition to the PD-L1 expression that had been reported by a previous study, 10 the number of PD-1 + TILs also seems to be a potential efficacy predictor for CIK treatment. Therefore, we conducted further IHC of CD4, CD8 and Foxp3 for the surgery-CIK group ( Figure   S5 ) and assessed the association between the number of PD-1 + TILs with clinical and immunological factors ( 
| DISCUSSION
Although several studies reported that adjuvant CIK cells treatment might improve the prognosis of HCC patients after curative therapies, contradictory evidence exists on the efficacy of this systemic therapy.
To determine the efficacy of adjuvant CIK therapy and reduce the impact of selection bias, we included a relatively large number of HCC patients receiving CIK therapy after curative resection and utilized one-to-one propensity score matching to balance the covariates between the two groups. Our results support the conclusion that adjuvant CIK cells therapy can improve the OS and DFS for HCC patients after curative resection.
Our study as well as the previous trials consistently showed that CIK cells treatment could reduce the risk of intrahepatic distant recurrence (beyond 2 cm from margin and <2 years after resection). 5 As early recurrence of HCC is related closely to the metastasis of remaining neoplastic cells, the benefit of clearing residual HCC cells using CIK cells might explain the reduced rates of early recurrence. 5 Additionally, in our study, patients in the surgery-CIK group were also found to have lower rates of late recurrence (beyond 2 years) than those in surgery-only group. A possible explanation for the inconsistency of late recurrence survival benefit between our and previous studies could be related to the number of infusion cycles and the duration of maintenance CIK treatment used. 4 In our study, almost 50% of patients received additional cycles of CIK infusions and 26 (17.9%) patients received more than 16 times CIK infusions (Table S4 ). Pan et al. 16 have reported that more than eight cycles of CIK transfusions could exhibit significantly better disease control than less than eight cycles for HCC patients. In addition to the direct tumour-killing effect of CIK cells treatment, there also could be an indirect mechanism reducing late tumour recurrence by controlling the replication of HBV.
It has been reported that autologous CIK cells could suppress HBV replication, 17 which is the predominant cause of HCC in our study;
hence, a long-term maintenance of CIK therapy could reduce late recurrence.
In our study, the survival of individuals in the surgery-CIK group varied significantly (OS range, 9-120 months), indicating that biomarkers that can differentiate between responders and non-responders are The correlation between the high number of PD-1 + TILs and favourable treatment response by CIK cells therapy we found was interesting. A recent review summarized that a high PD-L1 expression in tissue samples was a poor prognostic indicator for HCC after surgical resection. 7 This inconsistency between our data and previous studies may be due to the use of different antibodies and assay protocols as well as interpretative subjectivity. Firstly, evaluating the expression of PD-L1 in the previous study on tissue microarray might underestimate or overestimate the PD-L1 expression levels due to intratumoural heterogeneity. 23 In our study, the whole-tissue sections were used to assess PD-L1 staining. Secondly, PD-L1 is a type I transmembrane molecule and inhibits lymphocyte function when it is engaged by its receptors. It is believed that cell-surface expression of PD-L1 is the most immediately biologically relevant; however, the antibody used in previous two studies did not distinguish cytoplasmic and membranous patterns of PD-L1 staining. 23, 24 In our study, a newly developed anti-PD-L1 antibody was used (clone E1L3N, Cell Signaling Technology), which has been validated by recent studies. 25, 26 Our study has several limitations. Firstly, this is a single-centrebased retrospective study. Secondly, although propensity score matching could be beneficial in assessing the efficacy of CIK cells treatment, it might also cause selection bias. In this study, we reviewed all the early stage HCC patients who received CIK cells therapy after surgery in our centre from 2004 to 2011 to minimize this bias.
In conclusion, our study demonstrated that PD- 
